Beijing News News On May 22, Puli Pharma issued an announcement that iopamidol injection received the marketing authorization issued by the Dutch Committee for Drug Evaluation (CBG), and the indications are for neuroradiology, including lumbar spine, thoracic spine and Cervical spine and CT spondylography.
Iopamidol is a non-ionic, low-permeability iodinated contrast agent first developed by Bracco, which is widely used in various lumbar and cervical myelography, CT and CT enhancement, etc. diagnostic field. Iopamidol injection was first approved for marketing in France in May 1981, and has been approved for marketing in other European countries since then, including Italy, Germany, the Netherlands, the United Kingdom, etc. It was approved for marketing in the United States in December 1985, and in China in July 2002. Approved for listing.
Iopamidol injection is the first generic drug of contrast agent developed by Puli Pharmaceuticals, and it has submitted generic drug registration applications in China, Europe and the United States, and is a collinear product. The receipt of the marketing authorization from the Dutch Drug Evaluation Committee this time marks that Puli Pharma is qualified to sell iopamidol injection in the Netherlands, and also marks that Puli Pharma has successfully entered the field of contrast media.
Proofreading Janine